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Asthma and lower airway disease

Assessing differences in inhaled corticosteroid
response by self-reported race-ethnicity and
genetic ancestry among asthmatic subjects
Karen E. Wells, MPH,a Sonia Cajigal, MD,b Edward L. Peterson, PhD,a Brian K. Ahmedani, PhD,c Rajesh Kumar, MD,d
David E. Lanfear, MD, MS,b Esteban G. Burchard, MD, MPH,e,f and L. Keoki Williams, MD, MPHb,c
Detroit, Mich, Chicago,
Ill, and San Francisco, Calif
Background: Inhaled corticosteroids (ICSs) are the preferred
treatment for achieving asthma control. However, little is known
regarding the factors contributing to treatment response and
whether treatment response differs by population group.
Objective: We sought to assess behavioral, sociodemographic,
and genetic factors related to ICS response among African
American and European American subjects with asthma.
Methods: Study participants were part of the Study of Asthma
Phenotypes and Pharmacogenomic Interactions by Raceethnicity (SAPPHIRE). The analytic sample included asthmatic
subjects aged 12 to 56 years with greater than 12%
bronchodilator reversibility and percent predicted FEV1 of
between 40% and 90%. Participants received 6 weeks of inhaled
beclomethasone dipropionate. The primary measure of ICS
response was a change in Asthma Control Test (ACT) score; the
secondary measure was a change in prebronchodilator FEV1.
Adherence was measured with electronic monitors. Genetic
a
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ancestry was estimated for African American participants by
using genome-wide genotype data.
Results: There were 339 study participants; 242 self-identified
as African American and 97 as European American. Baseline
ACT score, percent predicted FEV1, degree of bronchodilator
response, and ICS adherence were significantly associated with
ICS response. A baseline ACT score of 19 or less was useful in
identifying those who would respond, as evidenced by the
significant dose-response relationship with ICS adherence.
Neither self-reported race-ethnicity among all participants nor
proportion of African ancestry among African American
participants was associated with ICS responsiveness.
Conclusions: Our findings suggest that baseline lung function
measures and self-reported asthma control predict ICS
response, whereas self-reported race-ethnicity and genetic
ancestry do not. (J Allergy Clin Immunol 2016;137:1364-9.)
Key words: Inhaled corticosteroids, Adherence, medication, asthma,
African Continental Ancestry Group, respiratory function tests

Discuss this article on the JACI Journal Club blog: www.jacionline.blogspot.com.
Repeated studies have demonstrated that long-term adherence
to inhaled corticosteroid (ICS) medication among asthmatic
subjects is poor.1-3 The consequence of this nonadherence is an
increased risk for severe asthma exacerbations, including the
need for hospitalization.4,5 Unaccounted for differences in medication adherence can also confound the relationship between
treatment and response,6 thereby obscuring the true effect of treatment. For example, previously described differences in ICS adherence between African American and European American subjects
could result in inaccurate inferences regarding treatment effect.7,8
We have previously shown that after accounting for medication
adherence, ICS response did not vary among African American
subjects based on genetic ancestry (ie, the proportion of African
ancestry vs European ancestry).9 These findings implied that as a
whole, a genetic contribution to treatment-related differences between African American and European American subjects with
asthma is likely to be small.
In the current analysis we extended our earlier findings by
expanding our study population of African American subjects and
by including a group of European American subjects with asthma.
This expanded study population allowed us to directly assess
whether ICS treatment response differed by either self-reported
race-ethnicity or genetic ancestry. All study subjects were part of the
Study for Asthma Phenotypes and Pharmacogenomic Interactions
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Abbreviations used
ACT: Asthma Control Test
BMI: Body mass index
ICS: Inhaled corticosteroid
SAPPHIRE: Study for Asthma Phenotypes and Pharmacogenomic
Interactions by Race-ethnicity

by Race-ethnicity (SAPPHIRE), had similar enrollment criteria,
and received the same 6-week ICS treatment course.

METHODS
Study population
The study population was comprised of participants in the Study of Asthma
Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE), which was approved by the Institutional Review Board at Henry Ford
Health System. Potentially eligible subjects were first identified through the
medical record based on age (12-56 years), prior diagnosis of asthma, and lack
of excluding diagnoses (ie, chronic obstructive pulmonary disease, congestive
heart failure, or both). Subjects who met these criteria and who lived in
southeast Michigan were invited for a clinical evaluation. Study participants
(or their guardians in the case of minors) provided written consent before
evaluation and study enrollment. Evaluation consisted of a staff-administered
survey, vital sign and anthropomorphic measurements, and lung function tests.
Race-ethnicity was based on subjects self-report at the initial study visit.
Lung function testing was performed with a Fleisch-type pneumotachometer
in accordance with 2005 American Thoracic Society/European Respiratory
Society guidelines for spirometry.10 Bronchodilator response was defined as a
greater than 12% improvement in FEV1 after albuterol administration. Albuterol
sulfate hydrofluoroalkane (360 mg, 4 puffs) was administered through a metereddose inhaler by using a spacer device (AeroChamber Plus Flow-Vu; Monaghan
Medical, Plattsburgh, NY), and lung function was measured 15 minutes later. Patients with 12% or less improvement in FEV1 after the first albuterol dose received
_18 years and 180 mg for those <18 years), and
a second dose (360 mg for those >
lung function was remeasured after another 15-minute wait.
To receive 6 weeks of observed ICS treatment, study participants had to
meet the following additional criteria: measured FEV1 of between 40% and
90% of predicted value (based on age, sex, height, and race-ethnicity),11
greater than 12% maximum bronchodilator reversibility, no smoking in the
preceding year and less than 10 pack years of total smoking, no ICSs or systemic corticosteroids used in the preceding 4-week period, and not pregnant
and not planning to become pregnant during the 6 weeks of ICS treatment.
Patients in the SAPPHIRE cohort who both met these criteria and agreed to
treatment received a 6-week course of beclomethasone dipropionate hydrofluoroalkane (320 mg/d administered as 2 puffs twice a day). Patients selfadministered the ICS medication through a metered-dose inhaler and use of
the previously described spacer device. At the end of the 6-week treatment
period, patients returned to complete another staff-administered questionnaire
and undergo lung function testing.

Assessment of exposure and outcomes
Patient medication adherence was assessed by using a DOSER-CT device
(Meditrack, Easton, Mass). The DOSER-CT was attached to the metered-dose
inhaler, and it counted each time that the inhaler was actuated. Adherence was
calculated as the total number of recorded actuations divided by the product of the
number of days between visits and 4 (the prescribed number of ICS puffs per day).
To assess changes in the level of asthma control, we measured differences
in Asthma Control Test (ACT; QualityMetric, Lincoln, RI) responses before
and after the 6-week course of ICS therapy. We also assessed changes in
prebronchodilator FEV1 between these time points.
Genome-wide genotype data were collected for the African American
SAPPHIRE participants in the treatment trial by using commercial arrays
(Affymetrix, Santa Clara, Calif). We have previously used these data to calculate

the proportion of West African ancestry (heretofore called African ancestry) in
these participants.12 Briefly, the software program LAMP was used to estimate
ancestry at each locus.13,14 We then estimated each patient’s global genetic
ancestry (ie, proportion of African ancestry) as the proportion of African alleles
among genotyped autosomal single nucleotide polymorphism locations.

Statistical analysis
The primary outcome of the study was ICS response, as measured by the
change in ACT score between the initial visit and the 6-week follow-up visit
after ICS treatment (ie, the composite ACT[6 weeks] 2 ACT[initial]). The secondary outcome was the percentage change in prebronchodilator FEV1 between
these time points (ie, FEV1[6 weeks] 2 FEV1[initial]/FEV1[initial]). Linear regression was used to assess the relationship between both outcome variables and
the following dependent variables: patient age, sex (coded male 5 0, coded
female 5 1), self-reported race-ethnicity (coded European American 5 0,
coded African American 5 1), body mass index (BMI), baseline percent predicted FEV1, baseline ACT score, and ICS adherence. Both age and BMI were
modeled for each unit increase (ie, years and kilograms per meters squared,
respectively) but were aggregated into 10-unit increments for presentation
in the tables. Based on the original validation of the ACT by Nathan et al,15
we also dichotomized the composite ACT score at a cut point of 19 (ie, patients
_19 were considered to have ‘‘not controlled’’ or ‘‘uncontrolled’’
with scores <
_20 were considered to have ‘‘controlled’’
asthma and patients with scores >
asthma). Similarly, we dichotomized lung function at 70% of predicted
FEV1 based on the midpoint for persistent moderate asthma in the current
US asthma guidelines.16 Therefore we stratified our models by both baseline
_19 and >
_20) and baseline percent predicted FEV1 (ie, <70%
ACT score (ie, <
and 70% to 90% [90% was the upper limit in the treatment group]) to assess
the relationship between exposure variables and outcomes within strata that
are considered to separate clinically meaningful differences in asthma control
and severity. Separate adjusted models limited to African American participants were used to assess the relationship between African ancestry and ICS
response.
As a post hoc analysis, we assessed factors associated with achieving self_20) after 6 weeks of ICS treatment
reported asthma control (ACT score >
among all patients whose asthma was not controlled at baseline (ACT score
<
_19). Logistic regression was used to assess the likelihood of achieving
control as a function of the following variables: patient age, sex (coded
male 5 0, coded female 5 1), self-reported race-ethnicity (coded European
American 5 0, coded African American 5 1), BMI, baseline percent predicted FEV1, and ICS adherence.
Analyses were performed with SAS statistical computing software (SAS
Institute, Cary, NC).17 A P value of less than .05 was considered statistically
significant.

RESULTS
Three hundred thirty-nine participants in the SAPPHIRE
cohort met the criteria and completed 6 weeks of observed ICS
treatment; 242 enrollees identified themselves as African American, and 97 identified as European American. The characteristics
of those subjects before and after stratification by race-ethnicity
are shown in Table I. When compared with European American
participants, African American study subjects were significantly
younger (mean, 32.5 vs 36.8 years), had a higher BMI (mean,
32.8 vs 29.4 kg/m2), and reported less well-controlled asthma
(mean ACT score, 18.1 vs 20.0). African American subjects
also had lower ICS adherence (mean, 0.76 vs 0.84), implying
that on average, African American participants took 76% of
their prescribed study dose compared with 84% in European
American participants. The average estimated proportion of
African ancestry in the African American participants was
79.9% 6 9.9% (SD), and the distribution is shown in Fig E1 in
this article’s Online Repository at www.jacionline.org.
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TABLE I. Characteristics of SAPPHIRE study participants (n 5 339)*

Variable

Age (y), mean 6 SD
Female sex, no. (%)
Self-reported race-ethnicity, no. (%)
African American
European American
Proportion of African Ancestry
BMI (kg/m2), mean 6 SD
ACT score at enrollment, mean 6 SDà
Percent predicted FEV1 at enrollment, mean 6 SD
Bronchodilator response at enrollment, mean 6 SD§
Change in ACT score, mean 6 SDk
Percentage change in prebronchodilator FEV1, mean 6 SD§
ICS adherence, mean 6 SD; median; and interquartile range{

Overall
(n 5 339)

African American
(n 5 242)

European
American
(n 5 97)

33.7 6 13.8
198 (58.4)

32.5 6 13.1
148 (61.2)

36.8 6 14.9
50 (51.6)

242 (71.4)
97 (28.6)
—
31.9 6 9.5
18.6 6 5.1
72.9 6 12.7
20.5 6 15.3
3.1 6 4.8
11.3 6 18.1
0.79 6 0.21; 0.84;
0.66-0.94

242 (100.0)
—
79.9 6 9.9
32.8 6 9.6
18.1 6 5.2
73.5 6 12.4
20.4 6 13.1
3.3 6 4.9
10.6 6 15.0
0.76 6 0.22; 0.80;
0.61-0.93

—
97 (100.0)
—
29.4 6 8.8
20.0 6 4.5
71.2 6 13.2
20.6 6 19.8
2.4 6 4.6
12.9 6 24.2
0.84 6 0.17; 0.89;
0.79-0.96

P valuey

<.01
.11
—
—
—
—
<.01
<.01
.13
.91
.11
.28
<.01

*Race-ethnicity was determined based on participant self-report.
P value for comparison of African American and European American subjects.
àACT scores of 19 or less represent poor asthma control, whereas those of 20 or greater represent good control.
§Bronchodilator response is measured as the percentage change in FEV1 after administration of inhaled albuterol.
kMeasured as the change between values measured at the time of enrollment and after 6 weeks of ICS treatment.
{The mean, median, and interquartile range represent the proportion of the prescribed amount of ICS taken over 6 weeks of treatment.

Over the 6-week course of ICS treatment, the average
improvement in ACT score and FEV1 was similar among African
American and European American participants. Improvements in
ACT score were 3.3 and 2.4 points for African American and European American subjects, respectively (P 5 .11). Similarly, prebronchodilator FEV1 improved by 10.6% and 12.9%, respectively
(P 5 .28).
These above findings were supported in Table II, which examined the factors associated with change in ACT score and FEV1
over the course of treatment. Self-identified race-ethnicity was
not associated with change in ACT score or FEV1, even after accounting for other variables, including ICS adherence. After adjusting for all of the variables shown, baseline ACT score
(parameter estimate [b] 5 20.71, P < .01), baseline percent predicted FEV1 (b 5 0.09, P < .01), degree of bronchodilator
response (b 5 0.05, P < .01), and ICS adherence (b 5 2.38,
P < .01) were significantly associated with the change in ACT
score. In contrast, only degree of bronchodilator response was
significantly associated with the change in FEV1 with treatment
in the multivariable model (b 5 0.72, P < .01).
Because the effects of ICS adherence can differ with underlying asthma control or lung function, we stratified our analyses
according to baseline ACT score (uncontrolled asthma 5 ACT
_19; controlled asthma 5 ACT score >
_20) and initial
score <
_70%; Table III).16 ICS
percent predicted FEV1 (ie, <70% and >
adherence was found to be a significant predictor of ACT
improvement among subjects with uncontrolled asthma at baseline (b 5 3.95, P 5 0.04). Although ICS adherence had a consistent and positive association with FEV1 improvement in both lung
_70%), this asfunction strata (percent predicted FEV1 <70% and >
sociation did not reach statistical significance in either group
(b 5 5.35, P 5 .49 and b 5 4.19, P 5 .22, respectively). Both
percent predicted FEV1 at baseline (b 5 0.11, P <.01) and degree
of bronchodilator response (b 5 0.09, P < .01) were significantly

associated with a change in ACT score among those whose
_19). Bronchodiasthma was initially uncontrolled (ACT score <
lator response was associated with FEV1 improvement among
those in both lung function strata (P < .01 for those with an initial
_70%). In none of these stratpercent predicted FEV1 <70% and >
ified models was self-reported race-ethnicity significantly associated with change in ACT score or change in FEV1.
We assessed whether African ancestry was a predictor of ICS
responsiveness (Table IV).16 Proportion of African ancestry was
unrelated to ICS response, as measured by both the change in
ACT score and the change in FEV1. African ancestry was similarly not related to ICS response, even after stratifying by baseline
level of asthma control and lung function.
As a post hoc analysis, we assessed factors associated with the
likelihood of achieving self-reported asthma control (ACT score
>
_20) after 6 weeks of ICS treatment among all subjects whose
_19).
asthma was not controlled at baseline (initial ACT score <
As shown in Table E1 in this article’s Online Repository at
www.jacionline.org, age, initial percent predicted FEV1, and degree of bronchodilator response were associated with the likelihood of reporting controlled asthma at the 6-week treatment
follow-up.

DISCUSSION
Few studies have described the relationship between ICS
treatment and the change in longitudinal measures of lung
function and asthma control among African American subjects
when compared with European American subjects. Here we
demonstrate that neither self-identified race-ethnicity nor genetic
ancestry were associated with ICS treatment response, as defined
by a change in either ACT score or FEV1. This study builds on our
earlier analysis in African American subjects alone, showing no
relationship between African ancestry and change in FEV1.9
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TABLE II. Predictors of ICS response measured as change in ACT score and change in lung function over 6 weeks of treatment*
Measure of ICS response
Percentage change in FEV1y

Change in ACT score*
Univariable
parameter
estimate (b)

Age (y)§
Sexk
Race-ethnicity{
BMI§
ACT score at baseline
Percent predicted FEV1 at baseline
Bronchodilator response at baseline
ICS adherence

20.10
0.43
0.93
0.35
20.68
20.03
0.09
2.23

6
6
6
6
6
6
6
6

0.19
0.53
0.58
0.28
0.04
0.02
0.02
1.26

P value

.62
.42
.11
.20
<.01
.21
<.01
.08

Multivariable
parameter
estimate (b)z

20.19
0.18
20.57
20.01
20.71
0.09
0.05
2.38

6
6
6
6
6
6
6
6

0.14
0.36
0.40
0.19
0.04
0.02
0.01
0.84

P value

.17
.62
.16
.96
<.01
<.01
<.01
<.01

Univariable
parameter
estimate (b)

20.07
1.09
22.36
0.40
21.02
20.65
0.80
3.78

6
6
6
6
6
6
6
6

0.72
1.99
2.17
1.04
0.19
0.07
0.05
4.75

P value

.92
.59
.28
.70
<.01
<.01
<.01
.43

Multivariable
parameter
estimate (b)z

20.68
1.21
22.52
0.45
20.24
20.13
0.71
5.68

6
6
6
6
6
6
6
6

0.57
1.52
1.69
0.81
0.16
0.07
0.06
3.55

P value

.24
.43
.14
.58
.12
.07
<.01
.11

*ICS response was measured as the numeric change in composite ACT score from enrollment to follow-up after 6 weeks of ICS treatment.
ICS response was measured as the percentage change in FEV1 from enrollment to follow-up after 6 weeks of ICS treatment (ie, FEV1[6 weeks] 2 FEV1[initial]/FEV1[initial]).
àAdjusted for all other variables listed.
§These variables were modeled for a single-unit increase (ie, years and kilograms per meters squared for age and BMI, respectively), but are aggregated here to show the effect of a
10-unit increase.
kReferent is male (coded male 5 0, coded female 5 1).
{Referent is European American (coded European American 5 0, coded African American 5 1).

TABLE III. Predictors of ICS response stratified by baseline ACT score and baseline FEV1*
Measure of ICS response
Percentage change in FEV1y

Change in ACT score*
_19
Initial ACT score <
Parameter
estimate (b)z

Age (y)§
Sexk
Race-ethnicity{
BMI§
ACT score at baseline
Percent predicted FEV1 at baseline
Bronchodilator response at baseline
ICS adherence

20.35 6
0.28 6
0.48 6
20.07 6
—
0.11 6
0.09 6
3.95 6

0.33
0.83
1.00
0.43
0.04
0.03
1.94

P value

.29
.73
.63
.88
—
<.01
<.01
.04

_20
Initial ACT score >
Parameter
estimate (b)z

0.06 6
0.33 6
20.17 6
0.13 6
—
0.03 6
0.02 6
1.41 6

0.14
0.40
0.41
0.22
0.02
0.03
0.95

P value

.70
.40
.69
.55
—
.16
.56
.14

Initial percent
predicted FEV1 <70%
Parameter
estimate (b)z

20.32 6
1.64 6
25.70 6
20.26 6
20.63 6
—
0.74 6
5.35 6

1.35
3.38
3.76
1.58
0.32
0.08
7.69

P value

.81
.63
.13
.87
.06
—
<.01
.49

Initial percent
_70%
predicted FEV1 >
Parameter
estimate (b)z

20.61 6
1.01 6
20.84 6
0.96 6
0.002 6
—
0.63 6
4.19 6

0.52
1.41
1.57
0.84
0.16
0.09
3.38

P value

.24
.48
.59
.25
.99
—
<.01
.22

*ICS response was measured as the numeric change in composite ACT score from enrollment to follow-up after 6 weeks of ICS treatment. The analysis was stratified by what was
_19) and controlled asthma (ACT score >
_20) at baseline.
clinically considered to be uncontrolled asthma (ACT score <
ICS response was measured as the percentage change in FEV1 from enrollment to follow-up after 6 weeks of ICS treatment (ie, FEV1[6 weeks] 2 FEV1[initial]/FEV1[initial]). The
analysis was stratified by percent predicted FEV1 measured at baseline (ie, a cut point of 70% of predicted FEV1, which is the midpoint for persistent moderate severity asthma in
the current US asthma guidelines).16
àAdjusted for all other variables listed.
§These variables were modeled for a single-unit increase (ie, years and kilograms per meters squared for age and BMI, respectively) but are aggregated here to show the effect of a
10-unit increase.
kReferent is male (coded male 5 0, coded female 5 1).
{Referent is European American (coded European American 5 0, coded African American 5 1).

The average improvement in FEV1 was 11.3% in our overall
study population. This is similar to our previous study, in which
we observed an 11.6% improvement in FEV1 after 6 weeks of
ICS therapy.9 This magnitude of FEV1 improvement is similar
to that described by some18 but higher than seen by others.19,20
Part of these differences might be due to the relatively high level
of medication adherence in the current study. We observed an
average adherence of 79%, which is higher than that usually
seen in unselected populations of ICS-treated asthmatic patients.3,4 This high level of adherence might be due to participants
knowing that adherence was being monitored, as has been

observed in other studies in which patients were conscious of
adherence monitoring.21-23
Although we found that neither self-identified race-ethnicity
nor ancestry was associated with ICS response, our earlier work
showed African ancestry to be associated with asthma exacerbations,24 nocturnal asthma,12 and lung function.25 Perhaps this
indicates that although the genetic determinates of ICS
controller response do not differ among African American and
European American subjects, determinates of intrinsic disease
severity do differ. The implication here would be that genetic
ancestry has little independent contribution to drug response
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TABLE IV. Assessment of genetic ancestry as a predictor of ICS response among African American subjects with asthma
Measure of ICS response
Percentage change in FEV1y

Change in ACT score*

All subjects

Initial ACT
_19
score <

Initial ACT
_20
score >

All subjects

Parameter
P
Parameter
P
Parameter
P
Parameter
P
estimate (b)z value estimate (b)z value estimate (b)z value estimate (b)z value

Age (y)§
20.44 6 0.19 .02 20.85 6 0.38 .03
0.04 6 0.23
Sexk
0.54 6 0.49 .27
0.57 6 0.95 .55
0.88 6 0.59
Proportion of
1.63 6 2.30 .48
1.37 6 4.69 .77
0.67 6 2.71
African
Ancestry{
BMI§
0.05 6 0.26 .84
0.13 6 0.49 .79 20.01 6 0.31
ACT score at
20.69 6 0.05 <.01
—
—
—
baseline
0.09 6 0.03 <.01
0.06 6 0.04 .19
0.06 6 0.04
Percent predicted
FEV1 at baseline
Bronchodilator
0.07 6 0.02 <.01
0.07 6 0.04 .07
0.07 6 0.04
response at
baseline
ICS adherence
3.92 6 1.12 <.01
7.84 6 2.22 <.01
2.45 6 1.37

Initial percent
predicted
_70%
FEV1 >

Initial percent
predicted
FEV1 <70%

.86
.14
.81

20.27 6 0.72
1.73 6 1.86
2.96 6 8.75

.71
.35
.74

.98
—

20.37 6 0.97
20.17 6 0.18

.14

20.10 6 0.10

Parameter
estimate (b)z

.25 20.67 6 0.71
.47
1.04 6 1.89
.83
2.45 6 8.51

.35
.58
.77

.70 21.38 6 1.99
.35 20.71 6 0.41

.49 20.08 6 1.06
.09
0.15 6 0.20

.94
.44

.29

—

—

—

0.52 6 0.13

<.01

11.53 6 9.08

.21

.05

0.52 6 0.09 <.01

.08

7.18 6 4.28

.10

2.08 6 1.77
3.07 6 4.22
4.80 6 22.52

P
Parameter
P
value estimate (b)z value

—

0.56 6 0.12 <.01
4.56 6 4.64

.33

*ICS response was measured as the numeric change in the composite ACT score from enrollment to follow-up after 6 weeks of ICS treatment. The ACT is stratified by what is
_19) and controlled asthma (ACT score >
_20).
clinically considered to be uncontrolled asthma (ACT score <
ICS response was measured as the percentage change in FEV1 from enrollment to follow-up after 6 weeks of ICS treatment (ie, FEV1[6 weeks] 2 FEV1[initial]/FEV1[initial]). The
analysis was stratified by percent predicted FEV1 measured at baseline (ie, a cut point of 70% of predicted FEV1, which is the midpoint for persistent moderate severity asthma in
the current US asthma guidelines).16
àAdjusted for all other variables listed.
§These variables were modeled for a single-unit increase (ie, years and kilograms per meters squared for age and BMI, respectively) but are aggregated here to show the effect of a
10-unit increase.
kReferent is male (coded male 5 0, coded female 5 1).
{Modeled as effect of each percentage increase in the proportion of overall African ancestry, as measured by using genome-wide genotype data.

beyond that already captured through baseline measures of
asthma severity, asthma control, and lung function. Another
potentially important implication of our findings is that differences in corticosteroid response are unlikely to account for
between-group differences in asthma control and complication
rates observed for African American and European American
subjects on a population level.26,27
It is important to note that the lack of association for overall
African ancestry should not be interpreted as an absence of
population-specific pharmacogenomics variants. Genetic variants
that influence drug response can occur exclusively or at different
frequencies between population groups.28,29 However, in a recent
review of the pharmacogenomics of the ICS response,30 none of
the existing genome-wide association studies included substantial
numbers of African American subjects. Therefore it is not known
whether the risk variants that have been identified to date are
generalizable to multiple population groups. Our results do not
address the generalizability of existing pharmacogenomic associations. Rather, our study implies that the sum effect of genetic variants influencing ICS response is likely to be similar among
subjects of African and European descent.
Our study is not without other limitations. First, the subjects in
our study were all members of a single large health system in
southeast Michigan; therefore the findings from our study might
not be generalizable to other patient populations within the United
States. However, the proportion of West African ancestry
estimated for the subjects in our study is similar to that reported
for other African American groups throughout the United
States.31,32

Second, because we did not have admixture estimates in our
European American participants, we could not assess the effect
of ancestry within this group. However, there is no a priori
reason to suspect that the effect of genetic ancestry would
have differed between groups, and the lower degree of continental ancestral variation in European American subjects would
have required a much greater number of subjects to perform
the same assessment.33,34
Third, although this study did include both African American
and European American subjects, the latter comprised a much
smaller number of patients. Consequently, additional replication
is needed to bolster our findings.
In this burgeoning era of personalized genomics, there is an
increased effort to target therapies to subjects most likely to
respond to treatment. Differences in medication response and
treatment-related side effects by race-ethnicity have now been
noted for a number of medications.35-37 Fortunately, African
American subjects, who as a group disproportionately have
asthma complications,38,39 did not demonstrate response differences to ICS medication, the cornerstone treatment for persistent
asthma. African American and European American subjects appeared to equally enjoy the benefits of ICS treatment for
improving asthma control and lung function. In identifying subjects most likely to benefit from treatment, our study suggested
that arguably more mundane factors, such as medication adherence, level of bronchodilator responsiveness, baseline lung function, and patient-reported asthma control, were consistently
predictive of ICS response. Therefore although pharmacogenomics might eventually pave the way for more targeted asthma
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treatment, fundamental characteristics of disease severity/control
and management remain primary concerns for selecting and optimizing treatment.16
Key messages
d

Neither self-reported race-ethnicity nor African ancestry
appears to be a major driver of ICS treatment response,
strongly suggesting that this cornerstone therapy is
equally beneficial in treating African American and European American subjects.

d

Easily obtained measures of lung function and asthma
control might be useful in assessing the likelihood of
response.
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FIG E1. Distribution of genetic ancestry among African American study
participants with genome-wide genotype data is shown (n 5 195). Each
column represents an individual study participant. The percentage of
African ancestry is depicted in blue, and the percentage of European
ancestry is depicted in yellow.
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TABLE E1. Likelihood of achieving asthma control among
subjects whose self-reported asthma was not controlled at
baseline*
aOR (95% CI)y

Age (y)à
Sex§
Race-ethnicityk
BMIà
Percent predicted FEV1 at baseline
Bronchodilator response at baseline
ICS adherence

0.71
1.62
0.60
0.70
1.05
1.03
1.01

(0.53-0.96)
(0.77-3.41)
(0.23-1.51)
(0.48-1.03)
(1.01-1.08)
(1.00-1.06)
(0.19-5.35)

P value

.02
.20
.28
.07
<.01
.03
.99

aOR, Adjusted odds ratio.
*Odds ratios represent the likelihood of achieving self-reported asthma control
_20) among patients whose baseline ACT score was 19 or less
(composite ACT score >
(ie, uncontrolled asthma).
The odds ratio for each dependent variable is adjusted for all of the other variables
shown.
àThese variables were modeled for a single-unit increase (ie, years and kilograms per
meters squared for age and BMI, respectively) but are aggregated here to show the
effect of a 10-unit increase.
§Referent is male (coded male 5 0, coded female 5 1).
kReferent is European American (coded European American 5 0, coded African
American 5 1).

